These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 14742751

  • 1. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.
    Taylor PJ, Kubler PA, Lynch SV, Allen J, Butler M, Pillans PI.
    Ann Pharmacother; 2004 Feb; 38(2):205-8. PubMed ID: 14742751
    [Abstract] [Full Text] [Related]

  • 2. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B, Kubanek M, Malek I, Vymetalova Y, Hoskova L, Podzimkova M, Kautzner J.
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [Abstract] [Full Text] [Related]

  • 3. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [Abstract] [Full Text] [Related]

  • 4. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 5. Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
    Navarro-Muñoz M, Bonet J, Bayés B, Lauzurica R, Blanco S, Romero R.
    Transplant Proc; 2007 Sep; 39(7):2259-63. PubMed ID: 17889157
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
    Wissing KM, Unger P, Ghisdal L, Broeders N, Berkenboom G, Carpentier Y, Abramowicz D.
    Transplantation; 2006 Sep 27; 82(6):771-8. PubMed ID: 17006324
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
    Aliabadi AZ, Mahr S, Dunkler D, Grömmer M, Zimpfer D, Wolner E, Grimm M, Zuckermann AO.
    Transplantation; 2008 Dec 27; 86(12):1771-6. PubMed ID: 19104420
    [Abstract] [Full Text] [Related]

  • 10. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW.
    Clin Pharmacol Ther; 2004 Aug 27; 76(2):167-77. PubMed ID: 15289793
    [Abstract] [Full Text] [Related]

  • 11. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA.
    Am J Cardiol; 2004 Nov 01; 94(9):1140-6. PubMed ID: 15518608
    [Abstract] [Full Text] [Related]

  • 12. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M, DISCOVERY PENTA investigators.
    Curr Med Res Opin; 2005 Aug 01; 21(8):1307-15. PubMed ID: 16083541
    [Abstract] [Full Text] [Related]

  • 13. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 01; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
    Stern RH, Yang BB, Hounslow NJ, MacMahon M, Abel RB, Olson SC.
    J Clin Pharmacol; 2000 Jun 01; 40(6):616-23. PubMed ID: 10868312
    [Abstract] [Full Text] [Related]

  • 15. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients.
    Mück W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, Neumayer HH, Kuhlmann J.
    Clin Pharmacol Ther; 1999 Mar 01; 65(3):251-61. PubMed ID: 10096257
    [Abstract] [Full Text] [Related]

  • 16. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
    Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P.
    Clin Pharmacol Ther; 2000 Oct 01; 68(4):391-400. PubMed ID: 11061579
    [Abstract] [Full Text] [Related]

  • 17. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 01; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 18. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH.
    Curr Med Res Opin; 2005 Nov 01; 21(11):1865-74. PubMed ID: 16307708
    [Abstract] [Full Text] [Related]

  • 19. Supratherapeutic response to ezetimibe administered with cyclosporine.
    Koshman SL, Lalonde LD, Burton I, Tymchak WJ, Pearson GJ.
    Ann Pharmacother; 2005 Sep 01; 39(9):1561-5. PubMed ID: 16030077
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin YW, Shim WJ, Ahn TH, Ho Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS.
    Clin Ther; 2007 Nov 01; 29(11):2365-73. PubMed ID: 18158077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.